Malignant Peripheral Nerve Sheath TumorSymptoms, Doctors, Treatments, Advances & More
Malignant Peripheral Nerve Sheath Tumor Overview
Learn About Malignant Peripheral Nerve Sheath Tumor
- Malignant peripheral nerve sheath tumor
- MPNST
- Malignant neurilemmoma
- Malignant neurofibroma
- Malignant schwannoma
- Neurofibrosarcoma
- Neurogenic sarcoma
Johns Hopkins Children's Center
Christine Pratilas is a Pediatrics specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Pratilas is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Osteotomy. Dr. Pratilas is board certified in American Board Of Pediatrics. Dr. Pratilas is currently accepting new patients.
Telehealth Video Visit
Aerang Kim is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma. Dr. Kim is board certified in Pediatrics: American Board Of Pediatrics, 2004 and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009.
Skip Viragh Outpatient Cancer Center
Christian Meyer is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Osteosarcoma, and Salpingo-Oophorectomy. Dr. Meyer is board certified in American Board Of Internal Medicine. Dr. Meyer is currently accepting new patients.
Summary: This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


